Our mission is to provide an innovative treatment for type 1 diabetes and improve the quality of life of patients.
Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes.
The company's lead product, DiaPep277® is currently in Phase III clinical trials for treating type 1 diabetes (T1D). DiaPep277® is a unique peptide representing a novel therapeutic approach to prevent the destruction of insulin producing cells in the pancreas.
To date, there is no therapy that can prevent the destruction of insulin secreting beta cells. DiaPep277® is designed to treat type 1 diabetes patients with residual insulin secreting cells in order to preserve their function. Potential target populations include newly diagnosed adult patients, type 1 diabetic children, people with a high risk of developing type 1 diabetes, and type 1 diabetes patients with slow progressing disease.
Andromeda is owned by Clal Biotechnology Industries (84%) and Teva Pharmaceutical Industries (16%).